Citations

Mayo Clinic

Clear

844 citation(s) found for "Yu, Roger C".

Identification of Women's Coronary Heart Disease and Risk Factors Prior to First Myocardial Infarction
Yawn, Barbara P. , Wollan, Peter C. , Jacobsen, Steven J. , Fryer, George E., Roger, Véronique L.

Journal of Women's Health | January 13, 2005 | Volume: 13 | Issue: 10 | Pages: 1087-1100

10.1089/jwh.2004.13.1087 | PMID 15650342 Get It

Anesthesia for Patients with Congenital Long QT Syndrome
Kies, Susan J., Hurley, Heather A., White, Roger D., Ackerman, Michael J. , Pabelick, Christina M.

Anesthesiology | December 23, 2004 | Volume: 102 | Issue: 1 | Pages: 204-210

10.1097/00000542-200501000-00029 | PMID 15618804 Get It

Long QT syndrome is a malfunction of cardiac ion channels resulting in impaired ventricular repolarization that can lead to a characteristic polymorphic ventricular tachycardia known as torsades de pointes. Stressors, by increasing sympathetic tone, and drugs can provoke torsade de pointes, leading to syncope, seizures, or sudden cardiac death in these patients. Beta blockade, implantation of cardioverter defibrillators, and left cardiac sympathetic denervation are used in the treatment of these patients. However, these treatment modalities do not guarantee the prevention of sudden cardiac death. Certain drugs, including anesthetic agents, are known to contribute to QT prolongation. After reviewing the literature the authors give recommendations for the anesthetic management of these patients in the perioperative period.
Gemcitabine and ISIS-2503 for Patients With Locally Advanced or Metastatic Pancreatic Adenocarcinoma: A North Central Cancer Treatment Group Phase II Trial
Erlichman, Charles , Steen, Preston D. , Foster, Nathan R. , Moore, Dennis F., Rowland, Kendrith M. , Nair, Suresh , Tschetter, Loren K., Fitch, Tom R., Alberts, Steven R. , Schroeder, Mark A.

Journal of Clinical Oncology | December 21, 2004 | Volume: 22 | Issue: 24 | Pages: 4944-4950

10.1200/jco.2004.05.034 | PMID 15611509 Get It

Purpose Gemcitabine remains the standard therapy for metastatic pancreatic adenocarcinoma (ACA), but has limited activity. ISIS-2503 is an antisense compound directed against H-ras with preclinical activity against pancreatic ACA in tumor models. The combination of ISIS-2503 and gemcitabine has been evaluated in a prior phase I study. Methods Patients with metastatic or locally advanced pancreatic ACA not amenable to surgery or local radiation received gemcitabine 1,000 mg/m2 intravenously over 30 minutes on days 1 and 8 and ISIS-2503 6 mg/kg/d as a continuous intravenous infusion over 14 days of an every-3-weeks cycle. Responses were monitored by radiologic imaging every 6 weeks. Results Forty-eight eligible patients were enrolled, 43 with metastatic disease. Median follow-up was 12.6 months (range, 2.2 to 16.8 months) for living patients. A median of four cycles of treatment was given (range, 1 to 18 cycles). All patients were assessable for response and toxicity. The 6-month survival percentage was 57.5% (95% CI, 44.9% to 73.5%) and the median survival was 6.6 months. The response rate was 10.4% (one complete response, four partial responses). Clinically significant toxicity was limited except for one fatal pulmonary embolism. Conclusion This study shows a promising response rate to the combination of gemcitabine and ISIS-2503 in patients with pancreatic ACA. The observed 6-month survival rate in these patients met our protocol-defined criteria for success. This regimen is tolerable, but is of unclear benefit. Additional studies evaluating the role of gemcitabine and ISIS-2503 in the treatment of pancreatic ACA should be considered.
A Specific Heptapeptide from a Phage Display Peptide Library Homes to Bone Marrow and Binds to Primitive Hematopoietic Stem Cells
Nowakowski, Grzegorz S. , Dooner, Mark S. , Valinski, Helen, Mihaliak, Alicia M., Quesenberry, Peter J. , Becker, Pamela S.

STEM CELLS | November 9, 2004 | Volume: 22 | Issue: 6 | Pages: 1030-1038

10.1634/stemcells.22-6-1030 | PMID 15536193 Get It

Prenatal Sonographic Detection of Uterine Dehiscence
Youngs, Diane J., Praska, Kathleen A., Harms, Roger W.

Journal of Diagnostic Medical Sonography | November 8, 2004 | Volume: 20 | Issue: 6 | Pages: 418-421

10.1177/8756479304268938 Get It

Uterine dehiscence is the incomplete separation of the myometrium at a uterine scar site, usually from a previous cesarean section. Because membranes remain intact, the prognosis for both mother and fetus is generally good. However, labor contractions may lead to progression and a complete uterine rupture, which can be catastrophic. The combination of abdominal pain, previous cesarean section, and the sonographic finding of ballooning membranes should suggest the diagnosis of uterine dehiscence.
Management issues in dyspepsia: current consensus and controversies
Vakil, Nimish , Delaney, Brendan , Marshall, Barry J. , Bytzer, Peter , Boer, Wink de, Jones, Roger , Agréus, Lars , Talley, Nicholas J. , Engstrand, Lars , Malfertheiner, Peter

Scandinavian Journal of Gastroenterology | September 29, 2004 | Volume: 39 | Issue: 10 | Pages: 913-918

10.1080/00365520410003452 | PMID 15513327 Get It

CHEMOPREVENTION OF PROSTATE CANCER IN MEN AT HIGH RISK: RATIONALE AND DESIGN OF THE REDUCTION BY DUTASTERIDE OF PROSTATE CANCER EVENTS (REDUCE) TRIAL
Andriole, Gerald L. , Bostwick, David G., Gomella, Leonard G. , Marberger, Michael, Tindall, Donald J., BREED, SHARON, Somerville, Matthew C. , Rittmaster, Roger S., GROUP, REDUCE STUDY, Brawley, Otis W. , GROUP, REDUCE STUDY

Journal of Urology | September 15, 2004 | Volume: 172 | Issue: 4 Part 1 | Pages: 1314-1317

10.1097/01.ju.0000139320.78673.2a | PMID 15371831 Get It

Heart Failure after Myocardial Infarction: Clinical Presentation and Survival
Hellermann, Jens, Jacobsen, Steven J. , Redfield, Margaret M. , Reeder, Guy S., Weston, Susan A., Roger, Véronique L.

European Journal of Heart Failure | August 24, 2004 | Volume: 7 | Issue: 1 | Pages: 119-125

10.1016/j.ejheart.2004.04.011 | PMID 15642543 Get It

Abstract Objectives To characterize the presentation and outcome of patients with heart failure (HF) after myocardial infarction (MI) according to left ventricular ejection fraction (LVEF) and test the hypothesis that the outcome of HF did not change over time. Background Little is known about the presentation and outcome of HF post-MI and how these may have changed over time. Methods Using the Rochester Epidemiology Project, all residents of Olmsted County, Minnesota who experienced an incident MI between 1979 and 1998 were identified; MI and HF were validated using standardized criteria. Subjects were followed through their community medical record. Results Between 1979 and 1998, 1915 patients with incident MI and no prior history of HF were identified. Of these, 791(41%) experienced new onset HF as defined by Framingham criteria during 6.6±5.0 years of follow-up. Forty-seven percent were men, mean age was 73±12 years. Forty-four percent had impaired LVEF, 18% preserved LVEF and 38% had no LVEF measurement within 60 days after the HF event. Median survival after HF onset was 4 years and at 5 years after HF onset, only 45% were alive. Older age, male sex, comorbidity, hypertension and no LVEF assessment were associated with increased risk of death, however, patients with impaired LVEF had the worst outcome. Over time, survival did not improve (HR for year: 1.00; 95% CI 0.99, 1.02; P=0.919) even after adjustment for baseline characteristics. Conclusion In this geographically defined cohort of patients with MI, new onset HF after the MI was frequent. When measured, LVEF was most frequently reduced, consistent with systolic heart failure. Mortality was high and did not decline over time and death was independently associated with male sex, older age, hypertension and comorbidity. It also differed according to LVEF, which was inconsistently ascertained in this setting, potentially representing practice opportunities.
On the feasibility of elastic wave visualization within polymeric solids using magnetic resonance elastography
Romano, Anthony J., Bucaro, Joseph A., Houston, Brian H. , Kugel, Jennifer L., Rossman, Phillip J. , Grimm, Roger C., Ehman, Richard L.

The Journal of the Acoustical Society of America | July 2, 2004 | Volume: 116 | Issue: 1 | Pages: 125-132

10.1121/1.1738841 | PMID 15295972 Get It

In this paper, the feasibility of extending previously described magnetic resonance elastography (MRE) dynamic displacement (and associated elasticity) measurement techniques, currently used successfully in tissue, to solid materials which have much higher shear rigidity and much lower nuclear spin densities, is considered. Based on these considerations, the MRE technique is modified in a straightforward manner and used to directly visualize shear wave displacements within two polymeric materials, one of which is relatively stiff.
Comparison of the Roche LightCycler vanA / vanB Detection Assay and Culture for Detection of Vancomycin-Resistant Enterococci from Perianal Swabs
Sloan, Lynne M., Uhl, J. R., Vetter, Emily A., Schleck, Cathy D. , Harmsen, William S. , Manahan, Janice M., Thompson, Roger, Rosenblatt, Jon E., Cockerill, Franklin R.

Journal of Clinical Microbiology | June 7, 2004 | Volume: 42 | Issue: 6 | Pages: 2636-2643

10.1128/jcm.42.6.2636-2643.2004 | PMID 15184445 Get It

ABSTRACT We compared the performance characteristics of a real-time PCR method, the LightCycler vanA / vanB detection assay (Roche Diagnostics Corporation, Indianapolis, Ind.) to that of Enterococcosel agar (BBL, Sparks, Md.) for direct detection of vancomycin-resistant enterococci (VRE) from 894 perianal stool swabs. For 421 of 894 swabs, the result for LightCycler PCR was compared to an Enterococcosel plate containing vancomycin at 6 μg/ml; for the remaining 473 swabs, the result for LightCycler PCR was compared to an Enterococcosel plate containing 8 μg/ml vancomycin. The LightCycler method produced considerably more positive results than either the Enterococcosel plate containing vancomycin at 6 μg/ml ( n = 25 versus n = 11; sensitivity, 100%; specificity, 97%; positive predictive value [PPV], 42%; negative predictive value [NPV], 100%) or the Enterococcosel plate containing vancomycin at 8 μg/ml ( n = 31 versus n = 10; sensitivity, 100%; specificity, 95%; PPV, 32%; NPV, 100%). When possible, additional testing, including culture, LightCycler PCR, and/or a conventional PCR method (PCR-restriction fragment length polymorphism assay), were performed on either the original specimens or original cultures or subsequent specimens for cases in which the original specimen was positive by LightCycler PCR but the Enterococcosel plate was negative. This additional testing demonstrated positive results for 7 of 14 (50%) evaluable discordant specimens which initially tested as LightCycler PCR positive but culture negative using the Enterococcosel plate containing vancomycin at 6 μg/ml and 12 of 17 (71%) evaluable discordant specimens which initially tested as LightCycler positive but culture negative using the Enterococcosel plate containing vancomycin at (8 μg/ml). These results demonstrate that the LightCycler VRE detection assay is considerably more sensitive than the standard culture method for detecting VRE directly from perianal swab specimens. The LightCycler assay also provides results much faster than culture (∼3.5 versus ≥72 h). The use of this test could have important implications for the effective control and prevention of nosocomial outbreaks of VRE.